



COMPANY NEWSLETTER

October 2017

MESSAGE FROM THE MANAGING DIRECTOR



This quarter has seen Proteomics International achieve one of its most significant milestones towards global commercialisation of PromarkerD, our world leading predictive diagnostic test for diabetic kidney disease, with the publication of the clinical study results in a major peer-reviewed medical journal. This story leads our forth newsletter of the year, which focuses on the details behind PromarkerD.

Through the quarter we have also engaged with Key Opinion Leaders across the globe, presenting our latest results on the Promarker™ platform and PromarkerD test at scientific meetings in Europe (16th Human Proteome Organisation World Congress, Dublin), Malaysia (International Proteomics Conference, Kuala Lumpur), and Australia (Australian Diabetes Society Annual Scientific Meeting, Perth). Such events also provided a focal point for direct engagement with potential partners.

To highlight our world-leading analytical services we embarked upon a trade mission to India in September visiting Hyderabad, Chennai, and Bangalore. There we met a number of clients and potential clients for biosimilars, biologics and vaccine characterisation, QC and stability testing. We extend our thanks to the Australian Trade Commissioner for opening the networking event in Hyderabad. In November we will also host site visits from a number of our international partners and clients, and in December we have a trade mission to Japan focused on PromarkerD.

Please get in touch if you would like to meet with us or know more about our products and services, or wish to receive a call from our Investor Relations team. In the meantime I hope you enjoy this summary and also invite you to explore the links to our website for further news.

Richard Lipscombe, PhD
Managing Director

IN THIS ISSUE

- ❑ **PromarkerD clinical study published in *Diabetes Care***
- ❑ **US PromarkerD patent expanded to all kidney disease**
- ❑ **How the PromarkerD test works**
- ❑ **Staff profile: Biostatistician**
- ❑ **R&D tax incentive boost**
- ❑ **Annual report 2017**

PromarkerD clinical study published in peer-reviewed international journal *Diabetes Care*


Proteomics International's flagship PromarkerD test was published in *Diabetes Care*, one of the top two diabetes journals globally. This is a key element of the company's commercialisation strategy in engaging with Key Opinion Leaders in the diabetes field.

The publication provides an important verification of the PromarkerD test, which can predict the onset of diabetic kidney disease better than any current measure. The clinical study, undertaken as a collaboration between Proteomics International and The University of Western Australia, shows "prediction of rapid decline in renal function independently of recognised clinical risk factors". The results show the test can detect a molecular fingerprint of the impending disease up to 4 years before clinical symptoms appear. This has the potential to save healthcare systems billions of dollars in costs with preventative diabetic kidney disease management.

The independent review and credibility awarded by this publication builds on the earlier foundation publication of the PromarkerD technology, and the presentation of the latest clinical data to the American Diabetes Association in San Diego in June. In combination, these milestones provide a springboard for further licensing deals in the year ahead.

Peters, K.E., et al., *Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II*. *Diabetes Care*, 2017.

The publication is available [online](#) for members of the American Diabetes Association ahead of print in the journal's November issue.



Staff Profile

Dr Kirsten Peters: Biostatistician

Dr Kirsten Peters joined Proteomics International in May 2015 as a biostatistician involved in the development of the company's predictive and diagnostic test for diabetic kidney disease - PromarkerD. Kirsten's role encompasses biostatistical analysis and study design in other diagnostic research programs from the company pipeline, including endometriosis and mesothelioma.

Kirsten graduated with a PhD in complex disease genetics in 2006 from the Australian National University in Canberra, before moving to Perth to work as a postdoctoral genetic epidemiologist and biostatistician in schizophrenia. Prior to joining Proteomics International, Kirsten's research career centred on the diabetes area with the Fremantle Diabetes Study at the University of Western Australia where she continues to hold a joint appointment.



PromarkerD
CHANGING LIVES

www.PromarkerD.com

US PromarkerD patent expanded to all kidney disease

Proteomics International was granted a new patent in the United States for its diagnostic test targeting diabetic kidney disease, PromarkerD, that expands cover to all kidney disease. The broader patent provides protection for the use of the PromarkerD panel for all nephropathy in the world's largest healthcare market, covering more than 320 million people.

Kidney disease is the ninth leading cause of death in the United States, accounting for 48,000 deaths a year, with related healthcare spending exceeding US\$50 billion annually. It is estimated that 30 million people in the United States suffer from chronic kidney disease, with about 44% of all new cases of kidney disease caused by diabetes. The condition has no symptoms in its early stages and can go undetected until it is very advanced.



How the PromarkerD test works:



The patient's blood is taken for testing in a pathology collection centre in a routine blood test.



The patient's blood is analysed in the testing laboratory using the PromarkerD assay.



The testing laboratory sends the results of the blood analysis to the PromarkerD hub for processing.



The PromarkerD hub analyses the blood results and determines the patient's risk of developing diabetic kidney disease in the next four years.

Once detected, diabetic kidney disease can be treated through medication and lifestyle changes to slow down the disease progression, and to prevent or delay the onset of kidney failure.

Images extracted from "The PromarkerD Test and How it Works". Visit www.PromarkerD.com to view the full video

R&D tax incentive boost

Proteomics International strengthened its balance sheet with receipt of \$786,225 in research and development tax incentive for the 2016-17 financial year. The company was eligible for the Australian Government rebate after spending \$1.82 million on R&D.

The company continues to invest heavily in the commercialisation of its world-leading diabetic kidney disease test, PromarkerD, its biomarker discovery program, and developing new fee-for-service methods.



Annual Report 2017

Please download [here](#) to read about the company's review of operations along with the likely developments in 2017-18.

PROTEOMICS – FAST FACT PANEL

COMPANY CONTACTS

Dr Richard Lipscombe
Managing Director

Mr Chuck Morrison
Head of Business Development

Mr Shane Herbert
Customers Services Manager

Dr Pearl Tan
Chief Operating Officer

Dr Scott Bringans
Research Manager

Mr Paul Hart (Canary Capital)
Investor Relations

AGENTS

India
Proteomics International – India
www.proteomicsindia.com
info-india@proteomics.com.au
P: + 91 8527 699 192

Malaysia/ Indonesia/ Thailand
First BASE Laboratories S/B
www.base-asia.com
peptide-my@base-asia.com
P: + 603 8943 3252

Singapore
Axil Scientific Pte Ltd
www.axilscientific.com
peptide@axilscientific.com
P: + 65 6775 7318

Japan
Leave a Nest Co. Ltd
www.leaveanest.com
info@leaveanest.com
P: + 81 3 6277 8041

Hong Kong/ China
Asia Bio Channel Limited
www.asiabiochannel.com
bcoissac@asiabiochannel.com
P: + 852 9845 4791

Latin America
LinkPharma LLC
www.linkpharma.co
customerservice@linkpharmaus.com
P: +1 813 319 3972

Listing
Australian Securities Exchange

Stock Code
ASX: PIQ

Canary Capital
www.canarycapital.com.au
phart@canarycapital.com.au
P: +61 3 9890 6846
M: +61 421 051 474

Cash Position
A\$1.5 million (30/09/2017)

Issued Capital – Ordinary shares
59.0 million

Market Capitalisation based on share price of 19.5 cents
A\$11.5 million

Proteomics International is a wholly owned subsidiary of Proteomics International Laboratories Limited (ASX: PIQ)

FOR FURTHER INFORMATION PLEASE CONTACT:

Proteomics International Laboratories Limited

 +61 8 9389 1992

 info@proteomics.com.au (general)
bd@proteomics.com.au (business development)

 www.proteomics.com.au
www.proteomicsinternational.com

 QEII Medical Centre
6 Verdun Street, Nedlands
Perth WA 6009 Australia

Forward looking statement

Any forward looking statements in this newsletter have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors many of which are outside Proteomics International Laboratories Limited's control. Important factors that could cause actual results to differ materially from any assumptions or expectations expressed or implied in this newsletter include known and unknown risks. As actual results may differ materially to any assumptions made in this newsletter, you are urged to view any forward looking statements contained in this newsletter with caution. This newsletter should not be relied on as a recommendation or forecast by Proteomics International Laboratories Limited, and should not be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.